Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
CDP-glucose + N-acylsphingosine
CDP + D-glucosyl-N-acylsphingosine
-
i.e. ceramide
i.e. glucosylceramide
?
TDP-glucose + N-acylsphingosine
TDP + D-glucosyl-N-acylsphingosine
-
i.e. ceramide
i.e. glucosylceramide
?
UDP + N-{6-[(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]hexanoyl}sphingosine
UDP + ?
-
-
-
?
UDP-glucose + 6-(((N-7-nitrobenz-2-oxa-1,3-diazol-4yl)amino)caproyl)sphingosine
UDP + ?
-
-
-
?
UDP-glucose + 6-([(N-7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino]caproyl)sphingosine
UDP + N-(6-((4-nitrobenz-2-oxa-1,3-diazol-7-yl)amino)caproyl)-O1-D-glucosyl-sphingosine
UDP-glucose + an N-acylsphingosine
UDP + a D-glucosyl-N-acylsphingosine
-
-
-
?
UDP-glucose + C6-ceramide
UDP + C6-glucosylceramide
-
with fluorescent NBD C6-ceramide resulting in NBD C6-glucosylceramide direct quantification of ceramide glycosylation catalyzed by GCS in cells and in tissues are possible
-
-
?
UDP-glucose + C6-ceramide
UDP + glucosyl-C6-ceramide
-
-
-
-
?
UDP-glucose + ceramide
UDP + D-glucosyl-ceramide
-
-
-
-
?
UDP-glucose + ceramide
UDP + glucosylceramide
UDP-glucose + decasphingosine
UDP + D-glucosyl-decasphingosine
-
-
-
?
UDP-glucose + dihydroceramide
UDP + D-glucosyl-dihydroceramide
-
mono-, tri-, and tetrahexosylceramides, the parasite enzyme is only active on the saturated substrate
product analysis
-
?
UDP-glucose + dihydrosphingosine
UDP + D-glucosyl-dihydrosphingosine
UDP-glucose + lauroyl amide
UDP + D-glucosyllauroyl amide
-
-
-
-
?
UDP-glucose + N-(epsilon-7-nitrobenz-2-oxa-1,3-diazol-4-yl-aminocaproyl)-D-erythro-sphingosine
?
-
-
-
-
?
UDP-glucose + N-6-[(7-nitrobenzo-2-oxa-1,3-diazol-4-yl)amino]hexanoyl-4-D-erythro-sphingosine
UDP + N-(6-((4-nitrobenz-2-oxa-1,3-diazol-7-yl)amino)caproyl)-O1-D-glucosyl-sphingosine
-
-
-
-
?
UDP-glucose + N-acylsphinganine
UDP + D-glucosyl-N-acylsphingosine
-
stereospecific and dependent on nature and chain length of N-acylsphinganine substrate
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
UDP-glucose + N-octanoyl sphingosine
UDP + D-glucosyl-N-octanoyl sphingosine
UDP-glucose + N-[7-(4-nitrobenzo-2-oxa-1,3-diazole)]-6-aminocaproyl-D-erythro-sphingosine
UDP + D-glucosyl-N-[7-(4-nitrobenzo-2-oxa-1,3-diazole)]-6-aminocaproyl-D-erythro-sphingosine
UDP-glucose + sphingosine
UDP + D-glucosyl-sphingosine
-
-
-
?
additional information
?
-
UDP-glucose + 6-([(N-7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino]caproyl)sphingosine
UDP + N-(6-((4-nitrobenz-2-oxa-1,3-diazol-7-yl)amino)caproyl)-O1-D-glucosyl-sphingosine
-
synthetic fluorescent substrate in liposomes for assay method development
-
-
?
UDP-glucose + 6-([(N-7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino]caproyl)sphingosine
UDP + N-(6-((4-nitrobenz-2-oxa-1,3-diazol-7-yl)amino)caproyl)-O1-D-glucosyl-sphingosine
-
synthetic fluorescent substrate in liposomes for assay method development
-
-
?
UDP-glucose + 6-([(N-7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino]caproyl)sphingosine
UDP + N-(6-((4-nitrobenz-2-oxa-1,3-diazol-7-yl)amino)caproyl)-O1-D-glucosyl-sphingosine
-
-
-
-
?
UDP-glucose + ceramide
UDP + glucosylceramide
-
-
-
-
?
UDP-glucose + ceramide
UDP + glucosylceramide
-
-
-
-
?
UDP-glucose + ceramide
UDP + glucosylceramide
-
key enzyme in the synthesis of major glycosphingolipids in vertebrates
glucosylceramide is the core structure of major glycosphingolipids
-
?
UDP-glucose + ceramide
UDP + glucosylceramide
-
-
-
-
?
UDP-glucose + ceramide
UDP + glucosylceramide
-
key enzyme in the synthesis of major glycosphingolipids in vertebrates
glucosylceramide is the core structure of major glycosphingolipids
-
?
UDP-glucose + ceramide
UDP + glucosylceramide
-
-
-
-
?
UDP-glucose + ceramide
UDP + glucosylceramide
-
-
glucosylceramide is the core structure of major glycosphingolipids
-
?
UDP-glucose + ceramide
UDP + glucosylceramide
-
ceramide and its metabolites are important mediators of apoptosis and cell survival
-
-
?
UDP-glucose + ceramide
UDP + glucosylceramide
-
-
-
-
?
UDP-glucose + ceramide
UDP + glucosylceramide
-
-
-
-
ir
UDP-glucose + ceramide
UDP + glucosylceramide
-
-
glucosylceramide is a precursor for synthesis of a multitude of higher sphingolipids
-
?
UDP-glucose + dihydrosphingosine
UDP + D-glucosyl-dihydrosphingosine
-
-
-
?
UDP-glucose + dihydrosphingosine
UDP + D-glucosyl-dihydrosphingosine
-
dihydrosphingosine is no substrate
-
-
?
UDP-glucose + dihydrosphingosine
UDP + D-glucosyl-dihydrosphingosine
-
dihydrosphingosine is no substrate
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
-
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
i.e. ceramide
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
i.e. ceramide
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
ceramide plays an important role in signal transduction, regulation, and cell homeostasis, thus its glycosylation may play a role in regulation of the cellular level of the bioactive lipid
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
initial key enzyme in glycosphingolipid biosynthesis
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
enzyme activity is regulated developmentally
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
-
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
i.e. ceramide
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
-
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
i.e. ceramide
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
i.e. ceramide
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
first step in synthesis of gangliosides
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
-
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
i.e. ceramide
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
Q58FH5
GCS is a key regulator of pathogenicity of Cryptococcus neoformans by ensuring cell cycle progression and growth of fungal cells in environments characterized by neutral/alkaline pH and physiological concentrations of CO2. Since these environments are characteristically found in the lung alveolar spaces, GCS regulates survival of Cryptococcus neoformans upon inhalation through the respiratory tract, with important implications for the dissemination of fungal cells to the brain and the development of meningo-encephalitis
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
Q58FH5
Cryptococcus neoformans Gcs1 expressed in Saccharomyces cerevisiae is unable to recognize 7-nitro-2-1,3-benzoxadiazol-4-yl-ceramide analogs as substrates
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
-
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
specific for UDP-glucose
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
i.e. ceramide
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
i.e. ceramide
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
first step in synthesis of gangliosides
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
-
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
acceptor substrate specificity, overview
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
i.e. ceramide
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
i.e. ceramide
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
i.e. ceramide
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
i.e. ceramide
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
i.e. ceramide
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
i.e. ceramide
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
i.e. ceramide
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
i.e. ceramide
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
overview: short-chain ceramide substrates
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
regulation of intracellular ceramide is closely related to drug resistance and DOX-induced apoptosis
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
enzyme is involved in renal growth, neuronal differentiation, the establishment of the water permeability barrier in keratinocytes, and multidrug resistance in cancer cell
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
enzyme is involved in renal growth, neuronal differentiation, the establishment of the water permeability barrier in keratinocytes, and multidrug resistance in cancer cell
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
ceramide plays an important role in signal transduction, regulation, and cell homeostasis, thus its glycosylation may play a role in regulation of the cellular level of the bioactive lipid
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
initial key enzyme in glycosphingolipid biosynthesis
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
enzyme activity is regulated developmentally
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
first step in synthesis of gangliosides
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
first step in synthesis of gangliosides
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
key step in biosynthesis of glycosphingolipids
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
-
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
i.e. ceramide
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
-
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
acceptor substrate specificity, overview
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
i.e. ceramide
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
i.e. ceramide
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
i.e. ceramide
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
i.e. ceramide
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
i.e. ceramide
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
i.e. ceramide
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
overview: short-chain ceramide substrates
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
ceramide plays an important role in signal transduction, regulation, and cell homeostasis, thus its glycosylation may play a role in regulation of the cellular level of the bioactive lipid
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
enzyme is required for normal permeability barrier homeostasis
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
initial key enzyme in glycosphingolipid biosynthesis
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
initial key enzyme in glycosphingolipid biosynthesis
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
enzyme activity is regulated developmentally
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
first step in the biosynthesis of glucosylceramide-based glycosphingolipids
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
the enzyme catalyzes a necessary step in the conversion of ceramide to glycosphingolipids
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
the enzyme catalyzes the initial step of glycosphingolipid biosynthesis
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
the transient formation of glucosylceramide is vital for a regular arrangement of lipids and proteins in lamellar bodies and for the maintenance of the epidermal barrier
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
Ugcg-deficient mice die between postnatal day 11 and postnatal day 24. Glycosphingolipids are required for brain maturation after birth
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
i.e. ceramide
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
first step in synthesis of gangliosides
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
-
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
key step in biosynthesis of glycosphingolipids
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
specific for ceramide substrate with trihydroxy sphingoside bases, ceramides with dihydroxy sphingoside bases are inactive, overview
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
i.e. ceramide
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
acceptor substrate specificity, overview
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
i.e. ceramide
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
i.e. ceramide
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
i.e. ceramide
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
i.e. ceramide
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
i.e. ceramide
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
i.e. ceramide
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
i.e. ceramide
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
i.e. ceramide
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
i.e. ceramide
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
stereospecific and dependent on nature and chain length of N-acylsphingosine substrate
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
UDP-glucose is the preferred donor substrate
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
ceramide plays an important role in signal transduction, regulation, and cell homeostasis, thus its glycosylation may play a role in regulation of the cellular level of the bioactive lipid
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
catalyzes the first step during the sequential addition of carbohydrate moieties for ganglioside biosynthesis
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
initial key enzyme in glycosphingolipid biosynthesis
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
initial key enzyme in glycosphingolipid biosynthesis
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
initial key enzyme in glycosphingolipid biosynthesis
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
enzyme activity is regulated developmentally
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
first step in synthesis of gangliosides
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
i.e. ceramide
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
catalyzes the first step during the sequential addition of carbohydrate moieties for ganglioside biosynthesis
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
-
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
i.e. ceramide
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
-
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
i.e. ceramide
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
i.e. ceramide
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
i.e. ceramide
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
i.e. ceramide
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
catalyzes the first step during the sequential addition of carbohydrate moieties for ganglioside biosynthesis
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
first step in synthesis of gangliosides
-
-
?
UDP-glucose + N-octanoyl sphingosine
UDP + D-glucosyl-N-octanoyl sphingosine
best substrate
-
?
UDP-glucose + N-octanoyl sphingosine
UDP + D-glucosyl-N-octanoyl sphingosine
-
best substrate
-
?
UDP-glucose + N-[7-(4-nitrobenzo-2-oxa-1,3-diazole)]-6-aminocaproyl-D-erythro-sphingosine
UDP + D-glucosyl-N-[7-(4-nitrobenzo-2-oxa-1,3-diazole)]-6-aminocaproyl-D-erythro-sphingosine
-
synthetic fluorescent ceramide substrate analogue for fluorescence enzyme assay
-
-
?
UDP-glucose + N-[7-(4-nitrobenzo-2-oxa-1,3-diazole)]-6-aminocaproyl-D-erythro-sphingosine
UDP + D-glucosyl-N-[7-(4-nitrobenzo-2-oxa-1,3-diazole)]-6-aminocaproyl-D-erythro-sphingosine
synthetic fluorescent ceramide substrate analogue for fluorescence enzyme assay
-
-
?
UDP-glucose + N-[7-(4-nitrobenzo-2-oxa-1,3-diazole)]-6-aminocaproyl-D-erythro-sphingosine
UDP + D-glucosyl-N-[7-(4-nitrobenzo-2-oxa-1,3-diazole)]-6-aminocaproyl-D-erythro-sphingosine
-
synthetic fluorescent ceramide substrate analogue for fluorescence enzyme assay
-
-
?
additional information
?
-
-
the enzyme has dual function as negative regulator of cell death mediated by proapoptotic factors and in catalyzing the formation of glucosylceramide, the core structure of major glycosphingolipids, ceramide generation might be a signal pathway
-
-
?
additional information
?
-
-
octanoyl dihydrosphingosine, decanoyl sphingosine, and stearoyl sphingosine are poor substrates
-
-
?
additional information
?
-
octanoyl dihydrosphingosine, decanoyl sphingosine, and stearoyl sphingosine are poor substrates
-
-
?
additional information
?
-
-
enzyme decreases apoptosis and induces multidrug resistance, functional interaction with RTN-1C modulates enzyme activity and regulates chemotherapeutic-induced apoptosis in neuroepithelioma cells
-
-
?
additional information
?
-
-
NBD ceramide is used as substrate
-
-
?
additional information
?
-
-
lipid profile of the parasite at different developmental stages, overview
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
UDP-glucose + an N-acylsphingosine
UDP + a D-glucosyl-N-acylsphingosine
-
-
-
?
UDP-glucose + ceramide
UDP + glucosylceramide
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
additional information
?
-
UDP-glucose + ceramide
UDP + glucosylceramide
-
key enzyme in the synthesis of major glycosphingolipids in vertebrates
glucosylceramide is the core structure of major glycosphingolipids
-
?
UDP-glucose + ceramide
UDP + glucosylceramide
-
key enzyme in the synthesis of major glycosphingolipids in vertebrates
glucosylceramide is the core structure of major glycosphingolipids
-
?
UDP-glucose + ceramide
UDP + glucosylceramide
-
-
-
-
?
UDP-glucose + ceramide
UDP + glucosylceramide
-
ceramide and its metabolites are important mediators of apoptosis and cell survival
-
-
?
UDP-glucose + ceramide
UDP + glucosylceramide
-
-
glucosylceramide is a precursor for synthesis of a multitude of higher sphingolipids
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
-
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
ceramide plays an important role in signal transduction, regulation, and cell homeostasis, thus its glycosylation may play a role in regulation of the cellular level of the bioactive lipid
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
initial key enzyme in glycosphingolipid biosynthesis
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
enzyme activity is regulated developmentally
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
-
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
-
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
first step in synthesis of gangliosides
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
-
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
Q58FH5
GCS is a key regulator of pathogenicity of Cryptococcus neoformans by ensuring cell cycle progression and growth of fungal cells in environments characterized by neutral/alkaline pH and physiological concentrations of CO2. Since these environments are characteristically found in the lung alveolar spaces, GCS regulates survival of Cryptococcus neoformans upon inhalation through the respiratory tract, with important implications for the dissemination of fungal cells to the brain and the development of meningo-encephalitis
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
-
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
first step in synthesis of gangliosides
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
regulation of intracellular ceramide is closely related to drug resistance and DOX-induced apoptosis
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
enzyme is involved in renal growth, neuronal differentiation, the establishment of the water permeability barrier in keratinocytes, and multidrug resistance in cancer cell
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
enzyme is involved in renal growth, neuronal differentiation, the establishment of the water permeability barrier in keratinocytes, and multidrug resistance in cancer cell
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
ceramide plays an important role in signal transduction, regulation, and cell homeostasis, thus its glycosylation may play a role in regulation of the cellular level of the bioactive lipid
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
initial key enzyme in glycosphingolipid biosynthesis
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
enzyme activity is regulated developmentally
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
first step in synthesis of gangliosides
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
first step in synthesis of gangliosides
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
key step in biosynthesis of glycosphingolipids
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
-
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
-
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
ceramide plays an important role in signal transduction, regulation, and cell homeostasis, thus its glycosylation may play a role in regulation of the cellular level of the bioactive lipid
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
enzyme is required for normal permeability barrier homeostasis
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
initial key enzyme in glycosphingolipid biosynthesis
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
initial key enzyme in glycosphingolipid biosynthesis
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
enzyme activity is regulated developmentally
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
first step in the biosynthesis of glucosylceramide-based glycosphingolipids
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
the enzyme catalyzes a necessary step in the conversion of ceramide to glycosphingolipids
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
the enzyme catalyzes the initial step of glycosphingolipid biosynthesis
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
the transient formation of glucosylceramide is vital for a regular arrangement of lipids and proteins in lamellar bodies and for the maintenance of the epidermal barrier
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
first step in synthesis of gangliosides
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
key step in biosynthesis of glycosphingolipids
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
ceramide plays an important role in signal transduction, regulation, and cell homeostasis, thus its glycosylation may play a role in regulation of the cellular level of the bioactive lipid
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
catalyzes the first step during the sequential addition of carbohydrate moieties for ganglioside biosynthesis
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
initial key enzyme in glycosphingolipid biosynthesis
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
initial key enzyme in glycosphingolipid biosynthesis
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
initial key enzyme in glycosphingolipid biosynthesis
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
enzyme activity is regulated developmentally
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
first step in synthesis of gangliosides
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
catalyzes the first step during the sequential addition of carbohydrate moieties for ganglioside biosynthesis
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
-
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
-
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
catalyzes the first step during the sequential addition of carbohydrate moieties for ganglioside biosynthesis
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
first step in synthesis of gangliosides
-
-
?
additional information
?
-
-
the enzyme has dual function as negative regulator of cell death mediated by proapoptotic factors and in catalyzing the formation of glucosylceramide, the core structure of major glycosphingolipids, ceramide generation might be a signal pathway
-
-
?
additional information
?
-
-
enzyme decreases apoptosis and induces multidrug resistance, functional interaction with RTN-1C modulates enzyme activity and regulates chemotherapeutic-induced apoptosis in neuroepithelioma cells
-
-
?
additional information
?
-
-
lipid profile of the parasite at different developmental stages, overview
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(+/-)-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol
-
(1R)-1-C-octyl-N-octyl-1,5-dideoxy-1,5-imino-D-glucitol
-
-
(1R)-N-butyl-1-C-butyl-1,5-dideoxy-1,5-imino-D-glucitol
-
-
(1S)-1-C-[5-(adamantan-1-yl-methoxy)-pentyl]-1-deoxynojirimycin
-
-
(1S)-N-butyl-1-C-[5-(adamantan-1-yl-methoxy)-pentyl]-1-deoxynojirimycin
-
-
(2R,3R,4R,5S)-1-(2-hydroxyethyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
i.e. miglitol
(2R,3R,4R,5S)-1-(5-[[3',5'-bis(trifluoromethyl)[1,1'-biphenyl]-4-yl]methoxy]pentyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
-
(2R,3R,4R,5S)-1-(5-[[4-(2,3-dihydro-1,4-benzodioxin-6-yl)phenyl]methoxy]pentyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
-
(2R,3R,4R,5S)-1-(5-[[4-(2-fluoropyridin-4-yl)phenyl]methoxy]pentyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
-
(2R,3R,4R,5S)-1-(5-[[4-(2H-1,3-benzodioxol-5-yl)phenyl]methoxy]pentyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
-
(2R,3R,4R,5S)-1-(5-[[4-(6-fluoropyridin-3-yl)phenyl]methoxy]pentyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
-
(2R,3R,4R,5S)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol
i.e. miglustat or Zavesca
(2R,3R,4R,5S)-1-[5-(benzyloxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
(2R,3R,4R,5S)-1-[5-(cyclohexylmethoxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
(2R,3R,4R,5S)-1-[5-(hexyloxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
(2R,3R,4R,5S)-1-[5-([(3R,10S,13S,17R)-10,13-dimethyl-17-[(2S)-7-methyloctan-2-yl]-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
(2R,3R,4R,5S)-1-[5-[(1R)-1-([1,1'-biphenyl]-4-yl)ethoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
(2R,3R,4R,5S)-1-[5-[(1S)-1-([1,1'-biphenyl]-4-yl)ethoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
(2R,3R,4R,5S)-1-[5-[(2'-fluoro[1,1'-biphenyl]-4-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
(2R,3R,4R,5S)-1-[5-[(2-fluoro[1,1'-biphenyl]-4-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
(2R,3R,4R,5S)-1-[5-[(3'-fluoro[1,1'-biphenyl]-4-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
(2R,3R,4R,5S)-1-[5-[(3-fluoro[1,1'-biphenyl]-4-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
(2R,3R,4R,5S)-1-[5-[(4'-chloro[1,1'-biphenyl]-4-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
(2R,3R,4R,5S)-1-[5-[(4'-fluoro[1,1'-biphenyl]-4-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
(2R,3R,4R,5S)-1-[5-[(4,8-dihydropyren-1-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
(2R,3R,4R,5S)-1-[5-[(5,8-dihydronaphthalen-2-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
(2R,3R,4R,5S)-1-[5-[([1,1'-biphenyl]-2-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
(2R,3R,4R,5S)-1-[5-[([1,1'-biphenyl]-3-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
(2R,3R,4R,5S)-1-[5-[([1,1'-biphenyl]-4-yl)methoxy]-2,2-difluoropentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
(2R,3R,4R,5S)-1-[5-[([1,1'-biphenyl]-4-yl)methoxy]-4,4-difluoropentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
(2R,3R,4R,5S)-1-[5-[([1,1'-biphenyl]-4-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-((adamantylmethoxy)hexyl)piperidine-3,4,5-triol
-
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-(5-(adamantylmethoxy)pentyl)piperidine-3,4,5-triol
i.e. AMP-DNM
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-(5-[[(2E,6E)-3,7,10-trimethylundeca-2,6,9-trien-1-yl]oxy]pentyl)piperidine-3,4,5-triol
-
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-(5-[[2-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methoxy]pentyl)piperidine-3,4,5-triol
-
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-(5-[[3-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methoxy]pentyl)piperidine-3,4,5-triol
-
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-(5-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methoxy]pentyl)piperidine-3,4,5-triol
-
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-(5-[[4-(2,3,4,5-tetrahydro-1,6-benzodioxocin-8-yl)phenyl]methoxy]pentyl)piperidine-3,4,5-triol
-
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-(5-[[4-(pyridin-3-yl)phenyl]methoxy]pentyl)piperidine-3,4,5-triol
-
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-(5-[[4-(pyridin-4-yl)phenyl]methoxy]pentyl)piperidine-3,4,5-triol
-
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-(5-[[4-(pyrimidin-5-yl)phenyl]methoxy]pentyl)piperidine-3,4,5-triol
-
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-(6-(adamantylhexyl)hexyl)piperidine-3,4,5-triol
-
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-(adamantylhept-6-en-1-yl)piperidine-3,4,5-triol
-
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-(adamantylhexyl)piperidine-3,4,5-triol
-
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-[5-[(2'-methoxy[1,1'-biphenyl]-4-yl)methoxy]pentyl]piperidine-3,4,5-triol
-
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-[5-[(2'-methyl[1,1'-biphenyl]-4-yl)methoxy]pentyl]piperidine-3,4,5-triol
-
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-[5-[(3'-methoxy[1,1'-biphenyl]-4-yl)methoxy]pentyl]piperidine-3,4,5-triol
-
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-[5-[(3'-methyl[1,1'-biphenyl]-4-yl)methoxy]pentyl]piperidine-3,4,5-triol
-
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-[5-[(4'-methoxy[1,1'-biphenyl]-4-yl)methoxy]pentyl]piperidine-3,4,5-triol
-
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-[5-[(4'-methyl[1,1'-biphenyl]-4-yl)methoxy]pentyl]piperidine-3,4,5-triol
-
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-[5-[(5-phenylpyridin-2-yl)methoxy]pentyl]piperidine-3,4,5-triol
-
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-[5-[(phenanthren-9-yl)methoxy]pentyl]piperidine-3,4,5-triol
-
(2S,3R)-2-(hydroxymethyl)pyrrolidin-3-ol
-
0.05 mM, about 15% inhibition
(2S,3R,4R,5S)-1-[5-(benzyloxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
(2S,3R,4R,5S)-1-[5-(cyclohexylmethoxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
(2S,3R,4R,5S)-1-[5-(hexyloxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
(2S,3R,4R,5S)-1-[5-([(3R,10S,13S,17R)-10,13-dimethyl-17-[(2S)-7-methyloctan-2-yl]-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-trio
-
(2S,3R,4R,5S)-1-[5-[(1R)-1-([1,1'-biphenyl]-4-yl)ethoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
(2S,3R,4R,5S)-1-[5-[(1S)-1-([1,1'-biphenyl]-4-yl)ethoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
(2S,3R,4R,5S)-1-[5-[(2-fluoro[1,1'-biphenyl]-4-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
(2S,3R,4R,5S)-1-[5-[(3-fluoro[1,1'-biphenyl]-4-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
(2S,3R,4R,5S)-1-[5-[(4,8-dihydropyren-1-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
(2S,3R,4R,5S)-1-[5-[(5,8-dihydronaphthalen-2-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
(2S,3R,4R,5S)-1-[5-[([1,1'-biphenyl]-2-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
(2S,3R,4R,5S)-1-[5-[([1,1'-biphenyl]-3-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
(2S,3R,4R,5S)-1-[5-[([1,1'-biphenyl]-4-yl)methoxy]-2,2-difluoropentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
(2S,3R,4R,5S)-1-[5-[([1,1'-biphenyl]-4-yl)methoxy]-4,4-difluoropentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
(2S,3R,4R,5S)-1-[5-[([1,1'-biphenyl]-4-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
(2S,3R,4R,5S)-2-(hydroxymethyl)-1-(5-(adamantylmethoxy)pentyl)piperidine-3,4,5-triol
i.e. ido-AMP-DNM
(2S,3R,4R,5S)-2-(hydroxymethyl)-1-(5-[[(2E,6E)-3,7,10-trimethylundeca-2,6,9-trien-1-yl]oxy]pentyl)piperidine-3,4,5-triol
-
(2S,3R,4R,5S)-2-(hydroxymethyl)-1-(5-[[2-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methoxy]pentyl)piperidine-3,4,5-triol
-
(2S,3R,4R,5S)-2-(hydroxymethyl)-1-(5-[[3-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methoxy]pentyl)piperidine-3,4,5-triol
-
(2S,3R,4R,5S)-2-(hydroxymethyl)-1-(6-(adamantylmethoxy)hexyl)piperidine-3,4,5-triol
-
(2S,3R,4R,5S)-2-(hydroxymethyl)-1-(6-adamantyloxyhexyl)piperidine-3,4,5-triol
-
(2S,3R,4R,5S)-2-(hydroxymethyl)-1-adamantylhexylpiperidine-3,4,5-triol
-
(2S,3R,4R,5S)-2-(hydroxymethyl)-1-[(6Z)-7-adamantylhept-6-en-1-yl]piperidine-3,4,5-triol
-
(2S,3R,4R,5S)-2-(hydroxymethyl)-1-[5-[(phenanthren-9-yl)methoxy]pentyl]piperidine-3,4,5-triol
-
(2S,3R,4S)-2-(hydroxymethyl)-4-octylpyrrolidin-3-ol
-
0.01 mM, about 70% inhibition
(2S,3R,4S)-4-butyl-2-(hydroxymethyl)pyrrolidin-3-ol
-
0.05 mM, about 30% inhibition
(D-threo)-1-(3',4'-ethylenedioxy)phenyl-2-palmitoylamino-3-pyrrolidino-1-propanol
-
the inhibitor is abolutely specific for the recombinant human enzyme and does not affect recombinant non-human enzymes from Gossypium arboreum, Caenorhabditis elegans, Aspergillus nidulans, Candida albicans, Pichia pastoris, Ustilago maydis, or Agrobacterium tumefaciens
(D-threo)-1-phenyl-2-decanoylamino-3-morpholino-1-propanol
-
specific inhibitor
1-phenyl-2-decanoylamino-3-morpholino-1-propanol
-
-
2-decanoylamido-3-morpholinopropiophenone
-
45% inhibition at 0.3 mM
4'-[([5-[(2R,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]pentyl]oxy)methyl][1,1'-biphenyl]-2-carbonitrile
-
4'-[([5-[(2R,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]pentyl]oxy)methyl][1,1'-biphenyl]-3-carbonitrile
-
4'-[([5-[(2R,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]pentyl]oxy)methyl][1,1'-biphenyl]-4-carbonitrile
-
arsenic trioxide
-
treatment of a human acute promyelocytic leukemia cell line (NB4) and adult T-cell leukemia/lymphoma (ATL) derived cells with arsenic trioxide induces accumulation of cytoxic levels of ceramide which results from de novo ceramide synthesis and inhibition of glucosylceramide synthase activity
CHAPS
-
i.e. 3-[(3-cholamidopropyl)dimethylammonio]-1propanesulfonate
D,L-threo-1-phenyl-2-(decanoylamino)-3-morpholino-1-propanol-HCl
-
accumulation of ceramide in the cells, higher amount in Z65 mutant than in strain K1
D,L-threo-1-phenyl-2-palmitoylamino-3-morpholino-1-propanol
-
enzyme inhibition in vitro and in vivo, in the latter case the compound also inhibits growth of the parasite
D-threo-1-phenyl-2-(decanoylamino)-3-morpholino-1-propanol-HCl
D-threo-2-palmitoylamino-3-pyrrolidino-1-propanol
Detergents
-
e.g. 0.5% Triton X-100 or 0.5% sodium deoxycholate; inhibition of enzyme due to permeabilization of microsomal membrane
diethyl dicarbonate
i.e. DEPC; reversible by hydroxylamine, UDP-glucose protects, inhibitor acts on histidine residues, including His193, within or near UDP-glucose binding site
DL-erythro-1-phenyl-2-decanoylamino-3-morpholino-1-propanol
the enzyme GCS inhibitor causes cytotoxic, antiproliferative, antiangiogenic and tumor-volume-reducing effects, modulating drug responses in cell lines both cytodestructive (as a drug sensitizer) and cytoprotective, effect on cell survival, overview. The inhibitor is not suitable to deplete cells of the neolacto glycosphingolipid series
-
DL-threo-1-phenyl-2-hexadecanoyl-amino-3-pyrrolidino-1-propanol
-
i.e. most active PDMP-type congener, specific and reversible, in vivo and in vitro
DL-threo-1-phenyl-2-palmitoylamino-3-morpholino-1-propanol
the enzyme GCS inhibitor causes cytotoxic, antiproliferative, antiangiogenic and tumor-volume-reducing effects, modulating drug responses in cell lines both cytodestructive (as a drug sensitizer) and cytoprotective, effect on cell survival, overview. The inhibitor is not suitable to deplete cells of the neolacto glycosphingolipid series
doxorubicin
-
i.e. DOX; increases enzyme activity in drug-sensitive cell line HL-60, but not in drug-resistant HL-60/ADR cell line; regulation of intracellular ceramide is closely related to drug resistance and DOX-induced apoptosis
ethyl-2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate
i.e. HA14-1, a reversible small molecule Bcl-2 inhibitor that also inhibits GlcT-1 enzyme activity. HA14-1 is a competitive and mixed-type inhibitor with respect to C6-NBD-ceramide and UDP-glucose, respectively. HA-14 does not possess structural homology with the substrates UDP-glucose and ceramide. Possible binding of GlcT-1 to Bcl-2
Genz-112638
-
inhibitor is tested in a murine model of Gaucher disease (D409V/null): mice that receive drug prior to significant accumulation of substrate show reduced levels of glucosylceramide and number of Gaucher cells in the spleen, lung and liver when compared to control. Treatment of older mice that already display significant amounts of tissue glucosylceramide results in arrest of further accumulation of the substrate and appearance of additional Gaucher cells in affected organs; substrate inhibition therapy with Genz-112638 represents an approach to enzyme therapy to treat the visceral pathology in Gaucher diseases
Genz-682452
a mall molecule inhibitor of enzyme GCS, that can traverse the bloodbrain barrier. Treating Fabry mice with Genz-682452 results in reduced tissue levels of including globotriaosylceramide and lysoglobotriaosylceramide and a delayed loss of the thermal nociceptive response. Greatest improvements are realized when the therapeutic intervention is administered to younger mice before they developed overt pathology
N-(5'-adamantan-1'-yl-methoxy)-pentyl-1-deoxynojirimycin
-
highly specific small molecule inhibitor of glucosylceramide synthase. When administered to mice and rats, it significantly reduces glycosphingolipid but not ceramide concentrations in various tissues. Treatment of ob/ob mice with the inhibitor normalizes their elevated tissue glucosylceramide levels, markedly lowers circulating glucose levels, improves oral glucose tolerance, reduced A1C, and improves insulin sensitivity in muscle and liver
N-(5'-adamantane-1'-yl-methoxy)-pentyl-1-deoxynojirimycin
-
pharmacological inhibition of glucosylceramide synthase enhances insulin sensitivity
N-adamantanemethoxypentyldeoxynojirimycin
-
N-adamantyl-6-[(2R,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]hexanamide
-
N-adamantyl-6-[(2S,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]hexanamide
-
N-butyl 1-deoxynojirimycin
-
-
N-butyl-1-deoxynojirimycin
-
-
N-butyl-2,4-di-O-butyl-1,5-dideoxy-1,5-imino-D-glucitol
-
1 mM, 29% inhibition
N-ethylmaleimide
attacks Cys207
N-octyl-2-O-octyl-1,5-dideoxy-1,5-imino-D-glucitol
-
-
N-octyl-4-O-octyl-1,5-dideoxy-1,5-imino-D-glucitol
-
-
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-(morpholin-4-yl)propan-2-yl]-2-(4-methoxyphenoxy)acetamide
-
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-(morpholin-4-yl)propan-2-yl]-5-(adamantylmethoxy)pentanamide
-
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-(morpholin-4-yl)propan-2-yl]nonanamide
-
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-(piperidin-1-yl)propan-2-yl]-2-(4-methoxyphenoxy)acetamide
-
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-(piperidin-1-yl)propan-2-yl]-5-(adamantylmethoxy)pentanamide
-
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-(piperidin-1-yl)propan-2-yl]nonanamide
-
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-(pyrrolidin-1-yl)propan-2-yl]-2-(4-methoxyphenoxy)acetamide
-
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-(pyrrolidin-1-yl)propan-2-yl]-5(adamantylmethoxy)pentanamide
-
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-(pyrrolidin-1-yl)propan-2-yl]nonanamide
-
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-[(2R,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]propan-2-yl]-2-(4-methoxyphenoxy)acetamide
-
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-[(2R,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]propan-2-yl]-5-(adamantylmethoxy)pentanamide
-
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-[(2R,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]propan-2-yl]nonanamide
-
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-[(2R,3S,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]propan-2-yl]-2-(4-methoxyphenoxy)acetamide
-
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-[(2R,3S,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]propan-2-yl]-5-(adamantylmethoxy)pentanamide
-
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-[(2R,3S,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]propan-2-yl]nonanamide
-
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-[(2S,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]propan-2-yl]-2-(4-methoxyphenoxy)acetamide
-
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-[(2S,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]propan-2-yl]-5-(adamantylmethoxy)pentanamide
-
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-[(2S,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]propan-2-yl]nonanamide
-
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-[(2S,3S,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]propan-2-yl]-2-(4-methoxyphenoxy)acetamide
-
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-[(2S,3S,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]propan-2-yl]-5-(adamantylmethoxy)pentanamide
-
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-[(2S,3S,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]propan-2-yl]nonanamide
-
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(2R,3R,4R)-3,4-dihydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]-1-hydroxypropan-2-yl]-2-(4-methoxyphenoxy)acetamide
-
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(2R,3R,4R)-3,4-dihydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]-1-hydroxypropan-2-yl]-5-(adamantylmethoxy)pentanamide
-
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(2R,3R,4R)-3,4-dihydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]-1-hydroxypropan-2-yl]nonanamide
-
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(2R,3R,4S)-3,4-dihydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]-1-hydroxypropan-2-yl]-2-(4-methoxyphenoxy)acetamide
-
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(2R,3R,4S)-3,4-dihydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]-1-hydroxypropan-2-yl]-5-(adamantylmethoxy)pentanamide
-
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(2R,3R,4S)-3,4-dihydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]-1-hydroxypropan-2-yl]nonanamide
-
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(2R,3S,4R)-3,4-dihydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]-1-hydroxypropan-2-yl]-2-(4-methoxyphenoxy)acetamide
-
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(2R,3S,4R)-3,4-dihydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]-1-hydroxypropan-2-yl]-5-(adamantylmethoxy)pentanamide
-
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(2R,3S,4R)-3,4-dihydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]-1-hydroxypropan-2-yl]nonanamide
-
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(2R,3S,4S)-3,4-dihydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]-1-hydroxypropan-2-yl]-2-(4-methoxyphenoxy)acetamide
-
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(2R,3S,4S)-3,4-dihydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]-1-hydroxypropan-2-yl]-5-(adamantylmethoxy)pentanamide
-
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(2R,3S,4S)-3,4-dihydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]-1-hydroxypropan-2-yl]nonanamide
-
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(2S,3R,4S)-3,4-dihydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]-1-hydroxypropan-2-yl]-2-(4-methoxyphenoxy)acetamide
-
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(2S,3R,4S)-3,4-dihydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]-1-hydroxypropan-2-yl]-5-(adamantylmethoxy)pentanamide
-
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(2S,3R,4S)-3,4-dihydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]-1-hydroxypropan-2-yl]nonanamide
-
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(2S,3S,4S)-3,4-dihydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]-1-hydroxypropan-2-yl]-2-(4-methoxyphenoxy)acetamide
-
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(2S,3S,4S)-3,4-dihydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]-1-hydroxypropan-2-yl]-5-(adamantylmethoxy)pentanamide
-
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(2S,3S,4S)-3,4-dihydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]-1-hydroxypropan-2-yl]nonanamide
-
N-[5-(adamantan-1-yl-ethoxy)-pentyl]-L-ido-1-deoxynojirimycin
-
-
N-[5-(adamantan-1-yl-methoxy)-pentyl]-1-deoxynojirimycin
N-[5-(adamantan-1-yl-methoxy)-pentyl]-L-ido-1-deoxynojirimycin
-
-
octyl glucoside
-
high concentration
Phospholipase A
-
treatment of microsomes results in loss of enzyme activity
-
Phospholipase C
-
treatment of microsomes results in loss of enzyme activity
-
PP55B
-
i.e. isopropylidene derivative of 5'-O-[[(2-decanoylamino-3-phenylpropylloxycarbonyl)amino]sulfonyl]uridine, 21% inhibition at 0.2 mM
threo-1-phenyl-2-decanoyl-amino-3-morpholino-1-propanol
-
inhibition at 0.005 mM
Zwittergent 3-12
-
complete inhibition
CDP-glucose
slight inhibition
CDP-glucose
-
slight inhibition
Cu2+
-
D-threo-1-phenyl-2-(decanoylamino)-3-morpholino-1-propanol-HCl
-
in vivo depletion of enzyme and accumulation of ceramide; not DL-diastereomer
D-threo-1-phenyl-2-(decanoylamino)-3-morpholino-1-propanol-HCl
-
accumulation of ceramide in the cells, higher amount in Z65 mutant than in strain K1
D-threo-1-phenyl-2-(decanoylamino)-3-morpholino-1-propanol-HCl
-
D-threo-1-phenyl-2-(decanoylamino)-3-morpholino-1-propanol-HCl
-
D-threo-1-phenyl-2-(decanoylamino)-3-morpholino-1-propanol-HCl
-
i.e. PDMP
D-threo-1-phenyl-2-(decanoylamino)-3-morpholino-1-propanol-HCl
-
i.e. PDMP
D-threo-1-phenyl-2-(decanoylamino)-3-morpholino-1-propanol-HCl
His193 mutants are not inhibited; i.e. PDMP
D-threo-2-palmitoylamino-3-pyrrolidino-1-propanol
-
-
D-threo-2-palmitoylamino-3-pyrrolidino-1-propanol
-
-
EDTA
no inhibition
Fe2+
-
Fe3+
-
N-butyldeoxynojirimycin
-
-
N-butyldeoxynojirimycin
-
N-butyldeoxynojirimycin
nonspecific inhibitor
N-butyldeoxynojirimycin
i.e. miglustat or Zavesca
N-butyldeoxynojirimycin
-
-
N-[5-(adamantan-1-yl-methoxy)-pentyl]-1-deoxynojirimycin
-
-
N-[5-(adamantan-1-yl-methoxy)-pentyl]-1-deoxynojirimycin
-
-
Tris
58% loss of activity at 0.2 M
Tris
-
at high concentration
Triton X-100
-
high concentration
Zn2+
-
additional information
-
induction of enzyme by inhibitors in presence of higher ceramide levels
-
additional information
-
no inhibition by EDTA
-
additional information
-
-
-
additional information
-
-
-
additional information
-
induction of enzyme by inhibitors in presence of higher ceramide levels; no inhibition by conduritol B epoxide
-
additional information
induction of enzyme by inhibitors in presence of higher ceramide levels; no inhibition by conduritol B epoxide
-
additional information
-
-
-
additional information
-
-
additional information
-
enzyme inhibition by antisense expression
-
additional information
identification and development of biphenyl substituted iminosugars as improved dual glucosylceramide synthase/neutral glucosylceramidase inhibitors, synthesis of a series of D-gluco- and L-ido-configured iminosugars N-modified with a variety of hydrophobic functional groups and of a series of biphenyl-substituted iminosugars of both configurations (D-gluco and L-ido), overview. Iminosugars featuring N-pentyloxymethylaryl substituents are considerably more potent inhibitors of glucosylceramide synthase than their aliphatic counterparts. Biphenyl-substituted L-ido-configured deoxynojirimycin derivatives are selective for glucosylceramidase and the nonlysosomal glucosylceramidase
-
additional information
synthesis and evaluation of a variety of iminosugar-based enzyme inhibitors that differ in the nature of the N substituent but also in configuration of the piperidine iminosugar, deoxynojirimycin-type iminosugars, overview. Usage of parent compound 1-phenyl-2-decanoyl-3-morpholino-1-propanol (PDMP)
-
additional information
GCS enzyme inhibitors affect the expression of lactosylceramide, neolacto, ganglio, and globo series glycosphingolipids in a panel of human breast cancer cell lines using flow cytometry, a commonly applied method investigating cell-surface glycosphingolipids after enzyme inhibition, overview
-
additional information
-
-
-
additional information
-
no inhibition by DTT
-
additional information
no inhibition by DTT
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.174
(1R)-1-C-octyl-N-octyl-1,5-dideoxy-1,5-imino-Dglucitol
Homo sapiens
-
-
0.609
(1R)-N-butyl-1-C-butyl-1,5-dideoxy-1,5-imino-D-glucitol
Homo sapiens
-
-
0.009
(1S)-1-C-[5-(adamantan-1-yl-methoxy)-pentyl]-1-deoxynojirimycin
Homo sapiens
-
-
0.025
(1S)-N-butyl-1-C-[5-(adamantan-1-yl-methoxy)-pentyl]-1-deoxynojirimycin
Homo sapiens
-
-
0.00002
(2R,3R,4R,5S)-1-(5-[[3',5'-bis(trifluoromethyl)[1,1'-biphenyl]-4-yl]methoxy]pentyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
pH and temperature not specified in the publication
0.00004
(2R,3R,4R,5S)-1-(5-[[4-(2,3-dihydro-1,4-benzodioxin-6-yl)phenyl]methoxy]pentyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
pH and temperature not specified in the publication
0.00015
(2R,3R,4R,5S)-1-(5-[[4-(2-fluoropyridin-4-yl)phenyl]methoxy]pentyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
pH and temperature not specified in the publication
0.000025
(2R,3R,4R,5S)-1-(5-[[4-(2H-1,3-benzodioxol-5-yl)phenyl]methoxy]pentyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
pH and temperature not specified in the publication
0.00075
(2R,3R,4R,5S)-1-(5-[[4-(6-fluoropyridin-3-yl)phenyl]methoxy]pentyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
pH and temperature not specified in the publication
0.00075
(2R,3R,4R,5S)-1-[5-(benzyloxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
pH and temperature not specified in the publication
0.0005
(2R,3R,4R,5S)-1-[5-(cyclohexylmethoxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
pH and temperature not specified in the publication
0.001
(2R,3R,4R,5S)-1-[5-([(3R,10S,13S,17R)-10,13-dimethyl-17-[(2S)-7-methyloctan-2-yl]-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
pH and temperature not specified in the publication
0.00006
(2R,3R,4R,5S)-1-[5-[(1R)-1-([1,1'-biphenyl]-4-yl)ethoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
pH and temperature not specified in the publication
0.00007
(2R,3R,4R,5S)-1-[5-[(1S)-1-([1,1'-biphenyl]-4-yl)ethoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
pH and temperature not specified in the publication
0.000075
(2R,3R,4R,5S)-1-[5-[(2'-fluoro[1,1'-biphenyl]-4-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
pH and temperature not specified in the publication
0.000025
(2R,3R,4R,5S)-1-[5-[(2-fluoro[1,1'-biphenyl]-4-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
pH and temperature not specified in the publication
0.000025
(2R,3R,4R,5S)-1-[5-[(3'-fluoro[1,1'-biphenyl]-4-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
pH and temperature not specified in the publication
0.000025
(2R,3R,4R,5S)-1-[5-[(3-fluoro[1,1'-biphenyl]-4-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
pH and temperature not specified in the publication
0.000025
(2R,3R,4R,5S)-1-[5-[(4'-chloro[1,1'-biphenyl]-4-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
pH and temperature not specified in the publication
0.000025
(2R,3R,4R,5S)-1-[5-[(4'-fluoro[1,1'-biphenyl]-4-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
pH and temperature not specified in the publication
0.000003
(2R,3R,4R,5S)-1-[5-[(4,8-dihydropyren-1-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
pH and temperature not specified in the publication
0.000003
(2R,3R,4R,5S)-1-[5-[(5,8-dihydronaphthalen-2-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
pH and temperature not specified in the publication
0.00005
(2R,3R,4R,5S)-1-[5-[([1,1'-biphenyl]-2-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
pH and temperature not specified in the publication
0.000075
(2R,3R,4R,5S)-1-[5-[([1,1'-biphenyl]-3-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
pH and temperature not specified in the publication
0.00125
(2R,3R,4R,5S)-1-[5-[([1,1'-biphenyl]-4-yl)methoxy]-2,2-difluoropentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
pH and temperature not specified in the publication
0.00006
(2R,3R,4R,5S)-1-[5-[([1,1'-biphenyl]-4-yl)methoxy]-4,4-difluoropentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
pH and temperature not specified in the publication
0.00005
(2R,3R,4R,5S)-1-[5-[([1,1'-biphenyl]-4-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
pH and temperature not specified in the publication
0.0003
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-((adamantylmethoxy)hexyl)piperidine-3,4,5-triol
Homo sapiens
pH and temperature not specified in the publication
0.0002
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-(5-(adamantylmethoxy)pentyl)piperidine-3,4,5-triol
Homo sapiens
pH and temperature not specified in the publication
0.02
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-(5-[[(2E,6E)-3,7,10-trimethylundeca-2,6,9-trien-1-yl]oxy]pentyl)piperidine-3,4,5-triol
Homo sapiens
above, pH and temperature not specified in the publication
0.000025
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-(5-[[2-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methoxy]pentyl)piperidine-3,4,5-triol
Homo sapiens
pH and temperature not specified in the publication
0.000025
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-(5-[[3-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methoxy]pentyl)piperidine-3,4,5-triol
Homo sapiens
pH and temperature not specified in the publication
0.00002
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-(5-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methoxy]pentyl)piperidine-3,4,5-triol
Homo sapiens
pH and temperature not specified in the publication
0.000025
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-(5-[[4-(2,3,4,5-tetrahydro-1,6-benzodioxocin-8-yl)phenyl]methoxy]pentyl)piperidine-3,4,5-triol
Homo sapiens
pH and temperature not specified in the publication
0.002
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-(5-[[4-(pyridin-3-yl)phenyl]methoxy]pentyl)piperidine-3,4,5-triol
Homo sapiens
pH and temperature not specified in the publication
0.002
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-(5-[[4-(pyridin-4-yl)phenyl]methoxy]pentyl)piperidine-3,4,5-triol
Homo sapiens
pH and temperature not specified in the publication
0.002
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-(5-[[4-(pyrimidin-5-yl)phenyl]methoxy]pentyl)piperidine-3,4,5-triol
Homo sapiens
pH and temperature not specified in the publication
0.0003
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-(6-(adamantylhexyl)hexyl)piperidine-3,4,5-triol
Homo sapiens
pH and temperature not specified in the publication
0.02
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-(adamantylhept-6-en-1-yl)piperidine-3,4,5-triol
Homo sapiens
above, pH and temperature not specified in the publication
0.02
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-(adamantylhexyl)piperidine-3,4,5-triol
Homo sapiens
above, pH and temperature not specified in the publication
0.00005
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-[5-[(2'-methoxy[1,1'-biphenyl]-4-yl)methoxy]pentyl]piperidine-3,4,5-triol
Homo sapiens
pH and temperature not specified in the publication
0.000025
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-[5-[(2'-methyl[1,1'-biphenyl]-4-yl)methoxy]pentyl]piperidine-3,4,5-triol
Homo sapiens
pH and temperature not specified in the publication
0.00015
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-[5-[(3'-methoxy[1,1'-biphenyl]-4-yl)methoxy]pentyl]piperidine-3,4,5-triol
Homo sapiens
pH and temperature not specified in the publication
0.0001
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-[5-[(3'-methyl[1,1'-biphenyl]-4-yl)methoxy]pentyl]piperidine-3,4,5-triol
Homo sapiens
pH and temperature not specified in the publication
0.000025
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-[5-[(4'-methoxy[1,1'-biphenyl]-4-yl)methoxy]pentyl]piperidine-3,4,5-triol
Homo sapiens
pH and temperature not specified in the publication
0.0001
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-[5-[(4'-methyl[1,1'-biphenyl]-4-yl)methoxy]pentyl]piperidine-3,4,5-triol
Homo sapiens
pH and temperature not specified in the publication
0.0002
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-[5-[(5-phenylpyridin-2-yl)methoxy]pentyl]piperidine-3,4,5-triol
Homo sapiens
pH and temperature not specified in the publication
0.02
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-[5-[(phenanthren-9-yl)methoxy]pentyl]piperidine-3,4,5-triol
Homo sapiens
above, pH and temperature not specified in the publication
0.0002
(2S,3R,4R,5S)-1-[5-(benzyloxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
pH and temperature not specified in the publication
0.00007
(2S,3R,4R,5S)-1-[5-(cyclohexylmethoxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
pH and temperature not specified in the publication
0.001
(2S,3R,4R,5S)-1-[5-([(3R,10S,13S,17R)-10,13-dimethyl-17-[(2S)-7-methyloctan-2-yl]-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-trio
Homo sapiens
pH and temperature not specified in the publication
0.00003
(2S,3R,4R,5S)-1-[5-[(1R)-1-([1,1'-biphenyl]-4-yl)ethoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
pH and temperature not specified in the publication
0.00004
(2S,3R,4R,5S)-1-[5-[(1S)-1-([1,1'-biphenyl]-4-yl)ethoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
pH and temperature not specified in the publication
0.0000025
(2S,3R,4R,5S)-1-[5-[(2-fluoro[1,1'-biphenyl]-4-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
pH and temperature not specified in the publication
0.000005
(2S,3R,4R,5S)-1-[5-[(3-fluoro[1,1'-biphenyl]-4-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
pH and temperature not specified in the publication
0.000003
(2S,3R,4R,5S)-1-[5-[(4,8-dihydropyren-1-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
pH and temperature not specified in the publication
0.000003
(2S,3R,4R,5S)-1-[5-[(5,8-dihydronaphthalen-2-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
pH and temperature not specified in the publication
0.000025
(2S,3R,4R,5S)-1-[5-[([1,1'-biphenyl]-2-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
pH and temperature not specified in the publication
0.00007
(2S,3R,4R,5S)-1-[5-[([1,1'-biphenyl]-3-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
pH and temperature not specified in the publication
0.00002
(2S,3R,4R,5S)-1-[5-[([1,1'-biphenyl]-4-yl)methoxy]-2,2-difluoropentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
pH and temperature not specified in the publication
0.000015
(2S,3R,4R,5S)-1-[5-[([1,1'-biphenyl]-4-yl)methoxy]-4,4-difluoropentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
pH and temperature not specified in the publication
0.000008
(2S,3R,4R,5S)-1-[5-[([1,1'-biphenyl]-4-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
pH and temperature not specified in the publication
0.0001
(2S,3R,4R,5S)-2-(hydroxymethyl)-1-(5-(adamantylmethoxy)pentyl)piperidine-3,4,5-triol
Homo sapiens
pH and temperature not specified in the publication
0.0025
(2S,3R,4R,5S)-2-(hydroxymethyl)-1-(5-[[(2E,6E)-3,7,10-trimethylundeca-2,6,9-trien-1-yl]oxy]pentyl)piperidine-3,4,5-triol
Homo sapiens
pH and temperature not specified in the publication
0.000003
(2S,3R,4R,5S)-2-(hydroxymethyl)-1-(5-[[2-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methoxy]pentyl)piperidine-3,4,5-triol
Homo sapiens
pH and temperature not specified in the publication
0.000003
(2S,3R,4R,5S)-2-(hydroxymethyl)-1-(5-[[3-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methoxy]pentyl)piperidine-3,4,5-triol
Homo sapiens
pH and temperature not specified in the publication
0.00025
(2S,3R,4R,5S)-2-(hydroxymethyl)-1-(6-(adamantylmethoxy)hexyl)piperidine-3,4,5-triol
Homo sapiens
pH and temperature not specified in the publication
0.00008
(2S,3R,4R,5S)-2-(hydroxymethyl)-1-(6-adamantyloxyhexyl)piperidine-3,4,5-triol
Homo sapiens
pH and temperature not specified in the publication
0.02
(2S,3R,4R,5S)-2-(hydroxymethyl)-1-adamantylhexylpiperidine-3,4,5-triol
Homo sapiens
above, pH and temperature not specified in the publication
0.02
(2S,3R,4R,5S)-2-(hydroxymethyl)-1-[(6Z)-7-adamantylhept-6-en-1-yl]piperidine-3,4,5-triol
Homo sapiens
above, pH and temperature not specified in the publication
0.02
(2S,3R,4R,5S)-2-(hydroxymethyl)-1-[5-[(phenanthren-9-yl)methoxy]pentyl]piperidine-3,4,5-triol
Homo sapiens
above, pH and temperature not specified in the publication
0.00015
4'-[([5-[(2R,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]pentyl]oxy)methyl][1,1'-biphenyl]-2-carbonitrile
Homo sapiens
pH and temperature not specified in the publication
0.00005
4'-[([5-[(2R,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]pentyl]oxy)methyl][1,1'-biphenyl]-3-carbonitrile
Homo sapiens
pH and temperature not specified in the publication
0.00015
4'-[([5-[(2R,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]pentyl]oxy)methyl][1,1'-biphenyl]-4-carbonitrile
Homo sapiens
pH and temperature not specified in the publication
0.000024
Genz-112638
Mus musculus
-
-
0.02 - 0.04
N,N'-(5,5'-[2-(adamantan-1-yl)propane-1,3-diyl]bis-(oxy)bis(pentane-5,1-diyl))-bis(1-deoxynojirimycin)
0.01 - 0.02
N,N'-(5,5'-[2-(adamantan-1-yl)propane-1,3-diyl]bis-(oxy)bis(pentane-5,1-diyl))-bis(L-ido-1-deoxynojirimycin)
0.02 - 0.04
N,N'-(5,5'-[adamantan-1,3-diylbis(methylene)]bis(oxy)-bis(pentane-5,1-diyl))-bis(1-deoxynojirimycin)
0.005 - 0.01
N,N'-(5,5'-[adamantan-1,3-diylbis(methylene)]bis(oxy)-bis(pentane-5,1-diyl))-bis(L-ido-1-deoxynojirimycin)
0.0002
N-adamantanemethoxypentyldeoxynojirimycin
Homo sapiens
pH 5.2, 37°C
0.001
N-adamantyl-6-[(2R,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]hexanamide
Homo sapiens
pH and temperature not specified in the publication
0.0004
N-adamantyl-6-[(2S,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]hexanamide
Homo sapiens
pH and temperature not specified in the publication
0.164
N-octyl-2-O-octyl-1,5-dideoxy-1,5-imino-D-glucitol
Homo sapiens
-
-
0.134
N-octyl-4-O-octyl-1,5-dideoxy-1,5-imino-D-glucitol
Homo sapiens
-
-
0.0008
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-(morpholin-4-yl)propan-2-yl]-2-(4-methoxyphenoxy)acetamide
Homo sapiens
pH 5.2, 37°C
0.00075
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-(morpholin-4-yl)propan-2-yl]-5-(adamantylmethoxy)pentanamide
Homo sapiens
pH 5.2, 37°C
0.0008
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-(morpholin-4-yl)propan-2-yl]nonanamide
Homo sapiens
pH 5.2, 37°C
0.0008
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-(piperidin-1-yl)propan-2-yl]-2-(4-methoxyphenoxy)acetamide
Homo sapiens
pH 5.2, 37°C
0.0015
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-(piperidin-1-yl)propan-2-yl]-5-(adamantylmethoxy)pentanamide
Homo sapiens
pH 5.2, 37°C
0.001
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-(piperidin-1-yl)propan-2-yl]nonanamide
Homo sapiens
pH 5.2, 37°C
0.00005
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-(pyrrolidin-1-yl)propan-2-yl]-2-(4-methoxyphenoxy)acetamide
Homo sapiens
pH 5.2, 37°C
0.0001
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-(pyrrolidin-1-yl)propan-2-yl]-5(adamantylmethoxy)pentanamide
Homo sapiens
pH 5.2, 37°C
0.0001
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-(pyrrolidin-1-yl)propan-2-yl]nonanamide
Homo sapiens
pH 5.2, 37°C
0.01
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-[(2R,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]propan-2-yl]-2-(4-methoxyphenoxy)acetamide
Homo sapiens
pH 5.2, 37°C
0.01
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-[(2R,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]propan-2-yl]-5-(adamantylmethoxy)pentanamide
Homo sapiens
pH 5.2, 37°C
0.01
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-[(2R,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]propan-2-yl]nonanamide
Homo sapiens
pH 5.2, 37°C
0.01
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-[(2R,3S,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]propan-2-yl]-2-(4-methoxyphenoxy)acetamide
Homo sapiens
pH 5.2, 37°C
0.01
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-[(2R,3S,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]propan-2-yl]-5-(adamantylmethoxy)pentanamide
Homo sapiens
pH 5.2, 37°C
0.01
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-[(2R,3S,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]propan-2-yl]nonanamide
Homo sapiens
pH 5.2, 37°C
0.01
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-[(2S,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]propan-2-yl]-2-(4-methoxyphenoxy)acetamide
Homo sapiens
pH 5.2, 37°C
0.01
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-[(2S,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]propan-2-yl]-5-(adamantylmethoxy)pentanamide
Homo sapiens
pH 5.2, 37°C
0.01
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-[(2S,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]propan-2-yl]nonanamide
Homo sapiens
pH 5.2, 37°C
0.01
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-[(2S,3S,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]propan-2-yl]-2-(4-methoxyphenoxy)acetamide
Homo sapiens
pH 5.2, 37°C
0.01
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-[(2S,3S,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]propan-2-yl]-5-(adamantylmethoxy)pentanamide
Homo sapiens
pH 5.2, 37°C
0.01
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-[(2S,3S,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]propan-2-yl]nonanamide
Homo sapiens
pH 5.2, 37°C
0.01
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(2R,3R,4R)-3,4-dihydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]-1-hydroxypropan-2-yl]-2-(4-methoxyphenoxy)acetamide
Homo sapiens
pH 5.2, 37°C
0.01
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(2R,3R,4R)-3,4-dihydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]-1-hydroxypropan-2-yl]-5-(adamantylmethoxy)pentanamide
Homo sapiens
pH 5.2, 37°C
0.01
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(2R,3R,4R)-3,4-dihydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]-1-hydroxypropan-2-yl]nonanamide
Homo sapiens
pH 5.2, 37°C
0.01
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(2R,3R,4S)-3,4-dihydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]-1-hydroxypropan-2-yl]-2-(4-methoxyphenoxy)acetamide
Homo sapiens
pH 5.2, 37°C
0.01
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(2R,3R,4S)-3,4-dihydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]-1-hydroxypropan-2-yl]-5-(adamantylmethoxy)pentanamide
Homo sapiens
pH 5.2, 37°C
0.01
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(2R,3R,4S)-3,4-dihydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]-1-hydroxypropan-2-yl]nonanamide
Homo sapiens
pH 5.2, 37°C
0.01
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(2R,3S,4R)-3,4-dihydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]-1-hydroxypropan-2-yl]-2-(4-methoxyphenoxy)acetamide
Homo sapiens
pH 5.2, 37°C
0.01
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(2R,3S,4R)-3,4-dihydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]-1-hydroxypropan-2-yl]-5-(adamantylmethoxy)pentanamide
Homo sapiens
pH 5.2, 37°C
0.01
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(2R,3S,4R)-3,4-dihydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]-1-hydroxypropan-2-yl]nonanamide
Homo sapiens
pH 5.2, 37°C
0.01
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(2R,3S,4S)-3,4-dihydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]-1-hydroxypropan-2-yl]-2-(4-methoxyphenoxy)acetamide
Homo sapiens
pH 5.2, 37°C
0.01
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(2R,3S,4S)-3,4-dihydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]-1-hydroxypropan-2-yl]-5-(adamantylmethoxy)pentanamide
Homo sapiens
pH 5.2, 37°C
0.01
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(2R,3S,4S)-3,4-dihydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]-1-hydroxypropan-2-yl]nonanamide
Homo sapiens
pH 5.2, 37°C
0.01
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(2S,3R,4S)-3,4-dihydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]-1-hydroxypropan-2-yl]-2-(4-methoxyphenoxy)acetamide
Homo sapiens
pH 5.2, 37°C
0.01
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(2S,3R,4S)-3,4-dihydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]-1-hydroxypropan-2-yl]-5-(adamantylmethoxy)pentanamide
Homo sapiens
pH 5.2, 37°C
0.01
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(2S,3R,4S)-3,4-dihydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]-1-hydroxypropan-2-yl]nonanamide
Homo sapiens
pH 5.2, 37°C
0.01
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(2S,3S,4S)-3,4-dihydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]-1-hydroxypropan-2-yl]-2-(4-methoxyphenoxy)acetamide
Homo sapiens
pH 5.2, 37°C
0.01
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(2S,3S,4S)-3,4-dihydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]-1-hydroxypropan-2-yl]-5-(adamantylmethoxy)pentanamide
Homo sapiens
pH 5.2, 37°C
0.01
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(2S,3S,4S)-3,4-dihydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]-1-hydroxypropan-2-yl]nonanamide
Homo sapiens
pH 5.2, 37°C
0.001 - 0.005
N-[5-(adamantan-1-yl-ethoxy)-pentyl]-1-deoxynojirimycin
0.001 - 0.005
N-[5-(adamantan-1-yl-ethoxy)-pentyl]-L-ido-1-deoxynojirimycin
0.0002 - 0.0005
N-[5-(adamantan-1-yl-methoxy)-pentyl]-1-deoxynojirimycin
0.0001
N-[5-(adamantan-1-yl-methoxy)-pentyl]-L-ido-1-deoxynojirimycin
Mus musculus
-
in vivo inhibition of a cell culture
0.02
N,N'-(5,5'-[2-(adamantan-1-yl)propane-1,3-diyl]bis-(oxy)bis(pentane-5,1-diyl))-bis(1-deoxynojirimycin)
Mus musculus
-
in vivo inhibition of a cell culture
0.04
N,N'-(5,5'-[2-(adamantan-1-yl)propane-1,3-diyl]bis-(oxy)bis(pentane-5,1-diyl))-bis(1-deoxynojirimycin)
Mus musculus
-
in vitro inhibition of purified enzyme
0.01
N,N'-(5,5'-[2-(adamantan-1-yl)propane-1,3-diyl]bis-(oxy)bis(pentane-5,1-diyl))-bis(L-ido-1-deoxynojirimycin)
Mus musculus
-
in vitro inhibition of purified enzyme
0.02
N,N'-(5,5'-[2-(adamantan-1-yl)propane-1,3-diyl]bis-(oxy)bis(pentane-5,1-diyl))-bis(L-ido-1-deoxynojirimycin)
Mus musculus
-
in vivo inhibition of a cell culture
0.02
N,N'-(5,5'-[adamantan-1,3-diylbis(methylene)]bis(oxy)-bis(pentane-5,1-diyl))-bis(1-deoxynojirimycin)
Mus musculus
-
in vivo inhibition of a cell culture
0.04
N,N'-(5,5'-[adamantan-1,3-diylbis(methylene)]bis(oxy)-bis(pentane-5,1-diyl))-bis(1-deoxynojirimycin)
Mus musculus
-
in vitro inhibition of purified enzyme
0.005
N,N'-(5,5'-[adamantan-1,3-diylbis(methylene)]bis(oxy)-bis(pentane-5,1-diyl))-bis(L-ido-1-deoxynojirimycin)
Mus musculus
-
in vivo inhibition of a cell culture
0.01
N,N'-(5,5'-[adamantan-1,3-diylbis(methylene)]bis(oxy)-bis(pentane-5,1-diyl))-bis(L-ido-1-deoxynojirimycin)
Mus musculus
-
in vitro inhibition of purified enzyme
0.001
N-[5-(adamantan-1-yl-ethoxy)-pentyl]-1-deoxynojirimycin
Mus musculus
-
in vivo inhibition of a cell culture
0.005
N-[5-(adamantan-1-yl-ethoxy)-pentyl]-1-deoxynojirimycin
Mus musculus
-
in vitro inhibition of purified enzyme
0.001
N-[5-(adamantan-1-yl-ethoxy)-pentyl]-L-ido-1-deoxynojirimycin
Mus musculus
-
in vivo inhibition of a cell culture
0.005
N-[5-(adamantan-1-yl-ethoxy)-pentyl]-L-ido-1-deoxynojirimycin
Mus musculus
-
in vitro inhibition of purified enzyme
0.0002
N-[5-(adamantan-1-yl-methoxy)-pentyl]-1-deoxynojirimycin
Homo sapiens
-
-
0.0002
N-[5-(adamantan-1-yl-methoxy)-pentyl]-1-deoxynojirimycin
Mus musculus
-
in vivo inhibition of a cell culture
0.0005
N-[5-(adamantan-1-yl-methoxy)-pentyl]-1-deoxynojirimycin
Mus musculus
-
in vitro inhibition of purified enzyme
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Paul, P.; Lutz, T.M.; Osborn, C.; Kyosseva, S.; Elbein, A.D.; Towbin, H.; Radominska, A.; Drake, R.R.
Synthesis and characterization of a new class of inhibitors of membrane-associated UDP-glycosyltransferases
J. Biol. Chem.
268
12933-12938
1993
Mus musculus
brenda
Basu, S.; Kaufman, B.; Roseman, S.
Enzymatic synthesis of glucocerebroside by a glucosyltransferase from embryonic chicken brain
J. Biol. Chem.
248
1388-1394
1973
Cavia porcellus, Gallus gallus, Ovis aries, Homo sapiens, Rattus norvegicus, Sus scrofa
brenda
Shah, S.N.
UDP-glucose: ceramide glucosyltransferase of rat brain: an association with smooth microsomes and requirement of an intact membrane for enzyme activity
Arch. Biochem. Biophys.
159
143-150
1973
Rattus norvegicus, Rattus norvegicus Sprague-Dawley
brenda
Shukla, G.S.; Radin, N.S.
Glucosyceramide synthase of mouse kidney: further characterization with an improved assay method
Arch. Biochem. Biophys.
283
372-378
1990
Mus musculus
brenda
Matsuo, N.; Nomura, T.; Imokawa, G.
A rapid and simple assay method for UDP-glucose:ceramide glucosyltransferase
Biochim. Biophys. Acta
1116
97-103
1992
Rattus norvegicus
brenda
Vunnam, R.R.; Radin, N.S.
Short chain ceramides as substrates for glucocerebroside synthetase. Differences between liver and brain enzymes
Biochim. Biophys. Acta
573
73-82
1979
Mus musculus
brenda
Durieux, I.; Martel, M.B.; Got, R.
Solubilization of UDPglucose-ceramide glucosyltransferase from the Golgi apparatus
Biochim. Biophys. Acta
1024
263-266
1990
Sus scrofa
brenda
Coste, H.; Martel, M.B.; Azzar, G.; Got, R.
UDPglucose-ceramide glucosyltransferase from porcine submaxillary glands is associated with the Golgi apparatus
Biochim. Biophys. Acta
814
1-7
1985
Sus scrofa
brenda
Nakayama, M.; Kojima, M.; Ohnishi, M.; Ito, S.
Enzymatic formation of plant cerebroside: properties of UDP-glucose:ceramide glucosyltransferase in radish seedlings
Biosci. Biotechnol. Biochem.
59
1882-1886
1995
Raphanus sativus
brenda
Ichikawa, S.; Sakiyama, H.; Suzuki, G.; Hidari, K.I.P.J.; Hirabayashi, Y.
Expression cloning of a cDNA for human ceramide glucosyltransferase that catalyzes the first glycosylation step of glycosphingolipid synthesis
Proc. Natl. Acad. Sci. USA
93
4638-4643
1996
Homo sapiens (Q16739), Homo sapiens
brenda
Paul, P.; Kamisaka, Y.; Marks, D.L.; Pagano, R.E.
Purification and characterization of UDP-glucose:ceramide glucosyltransferase from rat liver Golgi membranes
J. Biol. Chem.
271
2287-2293
1996
Rattus norvegicus
brenda
Chujor, C.S.; Feingold, K.R.; Elias, P.M.; Holleran, W.M.
Glucosylceramide synthase activity in murine epidermis: quantitation, localization, regulation, and requirement for barrier homeostasis
J. Lipid Res.
39
277-285
1998
Mus musculus
brenda
Ichikawa, S.; Hirabayashi, Y.
Glucosylceramide synthase and glycosphingolipid synthesis
Trends Cell Biol.
8
198-202
1998
Caenorhabditis elegans, Mus musculus, Rattus norvegicus, Homo sapiens (Q16739)
brenda
Itoh, M.; Kitano, T.; Watanabe, M.; Kondo, T.; Yabu, T.; Taguchi, Y.; Iwai, K.; Tashima, M.; Uchiyama, T.; Okazaki, T.
Possible role of ceramide as an indicator of chemoresistance: decrease of the ceramide content via activation of glucosylceramide synthase and sphingomyelin synthase in chemoresistant leukemia
Clin. Cancer Res.
9
415-423
2003
Homo sapiens
brenda
Marks, D.L.; Wu, K.; Paul, P.; Kamisaka, Y.; Watanabe, R.; Pagano, R.E.
Oligomerization and topology of the Golgi membrane protein glucosylceramide synthase
J. Biol. Chem.
274
451-456
1999
Homo sapiens, Rattus norvegicus
brenda
Wu, K.; Marks, D.L.; Watanabe, R.; Paul, P.; Rajan, N.; Pagano, R.E.
Histidine-193 of rat glucosylceramide synthase resides in a UDP-glucose-and inhibitor (D-threo-1-phenyl-2-decanoylamino-3-morpholinopropan-1-ol)-binding region: a biochemical and mutational study
Biochem. J.
341
395-400
1999
Homo sapiens (Q16739), Rattus norvegicus (Q9R0E0)
-
brenda
Shayman, J.A.; Abe, A.
Glucosylceramide synthase: assay and properties
Methods Enzymol.
311
42-49
2000
Canis lupus familiaris, Homo sapiens, Homo sapiens (Q16739)
brenda
Marks, D.L.; Paul, P.; Kamisaka, Y.; Pagano, R.E.
Methods for studying glucosylceramide synthase
Methods Enzymol.
311
50-59
2000
Gallus gallus, Homo sapiens, Homo sapiens (Q16739), Mus musculus, Rattus norvegicus, Rattus norvegicus (Q9R0E0), Rattus norvegicus Sprague-Dawley, Sus scrofa
brenda
Leipelt, M.; Warnecke, D.C.; Hube, B.; Zahringer, U.; Heinz, E.
Characterization of UDP-glucose: ceramide glucosyltransferases from different organisms
Biochem. Soc. Trans.
28
751-752
2000
Caenorhabditis elegans, Candida albicans, Komagataella pastoris
brenda
Marks, D.L.; Dominguez, M.; Wu, K.; Pagano, R.E.
Identification of active site residues in glucosylceramide synthase. A nucleotide-binding/catalytic motif conserved with processive beta-glycosyltransferases
J. Biol. Chem.
276
26492-26498
2001
Rattus norvegicus (Q9R0E0)
brenda
Saito, M.; Fukushima, Y.; Tatsumi, K.; Bei, L.; Fujiki, Y.; Iwamori, M.; Igarashi, T.; Sakakihara, Y.
Molecular cloning of Chinese hamster ceramide glucosyltransferase and its enhanced expression in peroxisome-defective mutant Z65 cells
Arch. Biochem. Biophys.
403
171-178
2002
Cricetulus griseus
brenda
Hayashi, Y.; Horibata, Y.; Sakaguchi, K.; Okino, N.; Ito, M.
A sensitive and reproducible assay to measure the activity of glucosylceramide synthase and lactosylceramide synthase using HPLC and fluorescent substrates
Anal. Biochem.
345
181-186
2005
Danio rerio, Cricetulus griseus
brenda
Hillig, I.; Warnecke, D.; Heinz, E.
An inhibitor of glucosylceramide synthase inhibits the human enzyme, but not enzymes from other organisms
Biosci. Biotechnol. Biochem.
69
1782-1785
2005
Homo sapiens
brenda
Di Sano, F.; Fazi, B.; Citro, G.; Lovat, P.E.; Cesareni, G.; Piacentini, M.
Glucosylceramide synthase and its functional interaction with RTN-1C regulate chemotherapeutic-induced apoptosis in neuroepithelioma cells
Cancer Res.
63
3860-3865
2003
Homo sapiens
brenda
Couto, A.S.; Caffaro, C.; Uhrig, M.L.; Kimura, E.; Peres, V.J.; Merino, E.F.; Katzin, A.M.; Nishioka, M.; Nonami, H.; Erra-Balsells, R.
Glycosphingolipids in Plasmodium falciparum. Presence of an active glucosylceramide synthase
Eur. J. Biochem.
271
2204-2214
2004
Plasmodium falciparum
brenda
Hillig, I.; Leipelt, M.; Ott, C.; Zahringer, U.; Warnecke, D.; Heinz, E.
Formation of glucosylceramide and sterol glucoside by a UDP-glucose-dependent glucosylceramide synthase from cotton expressed in Pichia pastoris
FEBS Lett.
553
365-369
2003
Gossypium arboreum
brenda
Kohyama-Koganeya, A.; Sasamura, T.; Oshima, E.; Suzuki, E.; Nishihara, S.; Ueda, R.; Hirabayashi, Y.
Drosophila glucosylceramide synthase: a negative regulator of cell death mediated by proapoptotic factors
J. Biol. Chem.
279
35995-36002
2004
Drosophila melanogaster
brenda
Gouaze, V.; Yu, J.Y.; Bleicher, R.J.; Han, T.Y.; Liu, Y.Y.; Wang, H.; Gottesman, M.M.; Bitterman, A.; Giuliano, A.E.; Cabot, M.C.
Overexpression of glucosylceramide synthase and P-glycoprotein in cancer cells selected for resistance to natural product chemotherapy
Mol. Cancer Ther.
3
633-639
2004
Homo sapiens
brenda
Aerts, J.M.; Ottenhoff, R.; Powlson, A.S.; Grefhorst, A.; van Eijk, M.; Dubbelhuis, P.F.; Aten, J.; Kuipers, F.; Serlie, M.J.; Wennekes, T.; Sethi, J.K.; ORahilly, S.; Overkleeft, H.S.
Pharmacological inhibition of glucosylceramide synthase enhances insulin sensitivity
Diabetes
56
1341-1349
2007
Mus musculus
brenda
Jennemann, R.; Sandhoff, R.; Langbein, L.; Kaden, S.; Rothermel, U.; Gallala, H.; Sandhoff, K.; Wiegandt, H.; Groene, H.J.
Integrity and barrier function of the epidermis critically depend on glucosylceramide synthesis
J. Biol. Chem.
282
3083-3094
2007
Mus musculus
brenda
Rittershaus, P.C.; Kechichian, T.B.; Allegood, J.C.; Merrill, A.H.; Hennig, M.; Luberto, C.; Del Poeta, M.
Glucosylceramide synthase is an essential regulator of pathogenicity of Cryptococcus neoformans
J. Clin. Invest.
116
1651-1659
2006
Cryptococcus neoformans (Q58FH5)
brenda
McEachern, K.A.; Fung, J.; Komarnitsky, S.; Siegel, C.S.; Chuang, W.L.; Hutto, E.; Shayman, J.A.; Grabowski, G.A.; Aerts, J.M.; Cheng, S.H.; Copeland, D.P.; Marshall, J.
A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease
Mol. Genet. Metab.
91
259-267
2007
Mus musculus
brenda
Faugeroux, V.; Genisson, Y.; Andrieu-Abadie, N.; Colie, S.; Levade, T.; Baltas, M.
C-Alkyl 5-membered ring imino sugars as new potent cytotoxic glucosylceramide synthase inhibitors
Org. Biomol. Chem.
4
4437-4439
2006
Mus musculus
brenda
Jennemann, R.; Sandhoff, R.; Wang, S.; Kiss, E.; Gretz, N.; Zuliani, C.; Martin-Villalba, A.; Jaeger, R.; Schorle, H.; Kenzelmann, M.; Bonrouhi, M.; Wiegandt, H.; Groene, H.J.
Cell-specific deletion of glucosylceramide synthase in brain leads to severe neural defects after birth
Proc. Natl. Acad. Sci. USA
102
12459-12464
2005
Mus musculus
brenda
Boucheron, C.; Desvergnes, V.; Compain, P.; Martin, O.R.; Lavi, A.; Mackeen, M.; Wormald, M.; Dwek, R.; Butters, T.D.
Design and synthesis of imino-sugar-based inhibitors of glucosylceramide synthase: the search for new therapeutic agents against Gaucher disease
Tetrahedron
16
1747-1756
2005
Homo sapiens
-
brenda
Marks, N.; Berg, M.J.; Saito, M.; Saito, M.
Glucosylceramide synthase decrease in frontal cortex of Alzheimer brain correlates with abnormal increase in endogenous ceramides: consequences to morphology and viability on enzyme suppression in cultured primary neurons
Brain Res.
1191
136-147
2008
Homo sapiens, Rattus norvegicus
brenda
Li, H.; Liu, T.; Zhang, Y.; Favre, S.; Bello, C.; Vogel, P.; Butters, T.D.; Oikonomakos, N.G.; Marrot, J.; Bleriot, Y.
New synthetic seven-membered 1-azasugars displaying potent inhibition towards glycosidases and glucosylceramide transferase
ChemBioChem
9
253-260
2008
Homo sapiens
brenda
Dbaibo, G.S.; Kfoury, Y.; Darwiche, N.; Panjarian, S.; Kozhaya, L.; Nasr, R.; Abdallah, M.; Hermine, O.; El-Sabban, M.; de The, H.; Bazarbachi, A.
Arsenic trioxide induces accumulation of cytotoxic levels of ceramide in acute promyelocytic leukemia and adult T-cell leukemia/lymphoma cells through de novo ceramide synthesis and inhibition of glucosylceramide synthase activity
Haematologica
92
753-762
2007
Homo sapiens
brenda
Xie, P.; Shen, Y.F.; Shi, Y.P.; Ge, S.M.; Gu, Z.H.; Wang, J.; Mu, H.J.; Zhang, B.; Qiao, W.Z.; Xie, K.M.
Overexpression of glucosylceramide synthase in associated with multidrug resistance of leukemia cells
Leuk. Res.
32
475-480
2008
Homo sapiens
brenda
Ramamoorthy, V.; Cahoon, E.B.; Li, J.; Thokala, M.; Minto, R.E.; Shah, D.M.
Glucosylceramide synthase is essential for alfalfa defensin-mediated growth inhibition but not for pathogenicity of Fusarium graminearum
Mol. Microbiol.
66
771-786
2007
Fusarium graminearum
brenda
Wennekes, T.; Lang, B.; Leeman, M.; van der Marel, G.A.; Smits, E.; Weber, M.; van Wiltenburg, J.; Wolberg, M.; Aerts, J.M.; Overkleeft, H.S.
Large-Scale Synthesis of the Glucosylceramide Synthase Inhibitor N-[5-(Adamantan-1-yl-methoxy)-pentyl]-1-deoxynojirimycin
Org. Process Res. Dev.
12
414-423
2008
Homo sapiens
-
brenda
Saadat, L.; Dupree, J.L.; Kilkus, J.; Han, X.; Traka, M.; Proia, R.L.; Dawson, G.; Popko, B.
Absence of oligodendroglial glucosylceramide synthesis does not result in CNS myelin abnormalities or alter the dysmyelinating phenotype of CGT-deficient mice
Glia
58
391-398
2010
Mus musculus (O88693)
brenda
Niimura, Y.; Moue, T.; Takahashi, N.; Nagai, K.I.
Modification of sphingoglycolipids and sulfolipids in kidney cell lines under heat stress: Activation of monohexosylceramide synthesis as a ceramide scavenger
Glycobiology
20
710-717
2010
Chlorocebus aethiops, Canis lupus familiaris, Chlorocebus sabaeus
brenda
Crespo, P.M.; Silvestre, D.C.; Gil, G.A.; Maccioni, H.J.; Daniotti, J.L.; Caputto, B.L.
c-Fos activates glucosylceramide synthase and glycolipid synthesis in PC12 cells
J. Biol. Chem.
283
31163-31171
2008
Homo sapiens
brenda
Ruckhaeberle, E.; Karn, T.; Hanker, L.; Gaetje, R.; Metzler, D.; Holtrich, U.; Kaufmann, M.; Rody, A.
Prognostic relevance of glucosylceramide synthase (GCS) expression in breast cancer
J. Cancer Res. Clin. Oncol.
135
81-90
2009
Homo sapiens
brenda
Marza, E.; Simonsen, K.T.; Faergeman, N.J.; Lesa, G.M.
Expression of ceramide glucosyltransferases, which are essential for glycosphingolipid synthesis, is only required in a small subset of C. elegans cells
J. Cell Sci.
122
822-833
2009
Caenorhabditis elegans, Caenorhabditis elegans (O18037), Caenorhabditis elegans (Q21054)
brenda
Gupta, V.; Patwardhan, G.A.; Zhang, Q.J.; Cabot, M.C.; Jazwinski, S.M.; Liu, Y.Y.
Direct quantitative determination of ceramide glycosylation in vivo: a new approach to evaluate cellular enzyme activity of glucosylceramide synthase (GlcT-1)
J. Lipid Res.
51
866-874
2010
Homo sapiens
brenda
Hisaki, H.; Okazaki, T.; Kubota, M.; Nakane, M.; Fujimaki, T.; Nakayama, H.; Nakagomi, T.; Tamura, A.; Masuda, H.
L-PDMP improves glucosylceramide synthesis and behavior in rats with focal ischemia
Neurol. Res.
30
979-984
2008
Rattus norvegicus
brenda
Patwardhan, G.; Zhang, Q.; Yin, D.; Gupta, V.; Bao, J.; Senkal, C.; Ogretmen, B.; Cabot, M.; Shah, G.; Sylvester, P.; Jazwinski, S.; Liu, Y.
A new mixed-backbone oligonucleotide against glucosylceramide synthase sensitizes multidrug-resistant tumors to apoptosis
PLoS ONE
4
e6938
2009
Homo sapiens, Mus musculus
brenda
Wennekes, T.; van den Berg, R.; Bonger, K.; Donker-Koopman, W.; Ghisaidoobe, A.; van der Marel, G.; Strijland, A.; Aerts, J.; Overkleeft, H.
Synthesis and evaluation of dimeric lipophilic iminosugars as inhibitors of glucosylceramide metabolism
Tetrahedron Asymmetry
20
836-846
2009
Mus musculus
-
brenda
Haynes, T.A.; Filippov, V.; Filippova, M.; Yang, J.; Zhang, K.; Duerksen-Hughes, P.J.
DNA damage induces down-regulation of UDP-glucose ceramide glucosyltransferase, increases ceramide levels and triggers apoptosis in p53-deficient cancer cells
Biochim. Biophys. Acta
1821
943-953
2012
Homo sapiens
brenda
Nomura, K.H.; Murata, D.; Hayashi, Y.; Dejima, K.; Mizuguchi, S.; Kage-Nakadai, E.; Gengyo-Ando, K.; Mitani, S.; Hirabayashi, Y.; Ito, M.; Nomura, K.
Ceramide glucosyltransferase of the nematode Caenorhabditis elegans is involved in oocyte formation and in early embryonic cell division
Glycobiology
21
834-848
2011
Caenorhabditis elegans
brenda
Gupta, V.; Bhinge, K.N.; Hosain, S.B.; Xiong, K.; Gu, X.; Shi, R.; Ho, M.Y.; Khoo, K.H.; Li, S.C.; Li, Y.T.; Ambudkar, S.V.; Jazwinski, S.M.; Liu, Y.Y.
Ceramide glycosylation by glucosylceramide synthase selectively maintains the properties of breast cancer stem cells
J. Biol. Chem.
287
37195-37205
2012
Homo sapiens
brenda
Kohyama-Koganeya, A.; Nabetani, T.; Miura, M.; Hirabayashi, Y.
Glucosylceramide synthase in the fat body controls energy metabolism in Drosophila
J. Lipid Res.
52
1392-1399
2011
Drosophila melanogaster
brenda
Ghisaidoobe, A.T.; van den Berg, R.J.; Butt, S.S.; Strijland, A.; Donker-Koopman, W.E.; Scheij, S.; van den Nieuwendijk, A.M.; Koomen, G.J.; van Loevezijn, A.; Leemhuis, M.; Wennekes, T.; van der Stelt, M.; van der Marel, G.A.; van Boeckel, C.A.; Aerts, J.M.; Overkleeft, H.S.
Identification and development of biphenyl substituted iminosugars as improved dual glucosylceramide synthase/neutral glucosylceramidase inhibitors
J. Med. Chem.
57
9096-9104
2014
Homo sapiens (Q16739)
brenda
Niino, S.; Nakamura, Y.; Hirabayashi, Y.; Nagano-Ito, M.; Ichikawa, S.
A small molecule inhibitor of Bcl-2, HA14-1, also inhibits ceramide glucosyltransferase
Biochem. Biophys. Res. Commun.
433
170-174
2013
Homo sapiens (Q16739)
brenda
van den Berg, R.J.; van Rijssel, E.R.; Ferraz, M.J.; Houben, J.; Strijland, A.; Donker-Koopman, W.E.; Wennekes, T.; Bonger, K.M.; Ghisaidoobe, A.B.; Hoogendoorn, S.; van der Marel, G.A.; Codee, J.D.; Overkleeft, H.S.; Aerts, J.M.
Synthesis and evaluation of hybrid structures composed of two glucosylceramide synthase inhibitors
ChemMedChem
10
2042-2062
2015
Homo sapiens (Q16739)
brenda
Alam, S.; Fedier, A.; Kohler, R.S.; Jacob, F.
Glucosylceramide synthase inhibitors differentially affect expression of glycosphingolipids
Glycobiology
25
351-356
2015
Homo sapiens (Q16739)
brenda
Ashe, K.M.; Budman, E.; Bangari, D.S.; Siegel, C.S.; Nietupski, J.B.; Wang, B.; Desnick, R.J.; Scheule, R.K.; Leonard, J.P.; Cheng, S.H.; Marshall, J.
Efficacy of enzyme and substrate reduction therapy with a novel antagonist of glucosylceramide synthase for Fabry disease
Mol. Med.
21
389-399
2015
Mus musculus (O88693), Mus musculus 129SvEv (O88693)
brenda
Chiu, W.H.; Su, W.C.; Li, C.L.; Chen, C.L.; Lin, C.F.
An increase in glucosylceramide synthase induces Bcl-xL-mediated cell survival in vinorelbine-resistant lung adenocarcinoma cells
Oncotarget
6
20513-20524
2015
Homo sapiens (Q16739)
brenda
Wegner, M.S.; Schoemel, N.; Gruber, L.; Oertel, S.B.; Kjellberg, M.A.; Mattjus, P.; Kurz, J.; Trautmann, S.; Peng, B.; Wegner, M.; Kaulich, M.; Ahrends, R.; Geisslinger, G.; Groesch, S.
UDP-glucose ceramide glucosyltransferase activates AKT, promoted proliferation, and doxorubicin resistance in breast cancer cells
Cell. Mol. Life Sci.
75
3393-3410
2018
Homo sapiens (Q16739)
brenda